Innovation and Access to Medicines for Neglected Populations: Could a Treaty Address a Broken Pharmaceutical R&D System?
Open Access
- 15 May 2012
- journal article
- essay
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 9 (5) , e1001218
- https://doi.org/10.1371/journal.pmed.1001218
Abstract
As part of a cluster of articles leading up to the 2012 World Health Report and critically reflecting on the theme of “no health without research,” Suerie Moon and colleagues argue for a global health R&D treaty to improve innovation in new medicines and strengthening affordability, sustainable financing, efficiency in innovation, and equitable health-centered governance.Keywords
This publication has 26 references indexed in Scilit:
- Expert Delphi survey on research and development into drugs for neglected diseasesBMC Health Services Research, 2011
- Driving a decade of change: HIV/AIDS, patents and access to medicines for allJournal of the International AIDS Society, 2011
- WHO Framework Convention on Tobacco Control: a key milestoneBulletin of the World Health Organization, 2010
- The UNITAID Patent Pool Initiative: Bringing Patents Together for the Common GoodThe Open AIDS Journal, 2010
- Prizes and Parasites: Incentive Models for Addressing Chagas DiseaseJournal of Law, Medicine & Ethics, 2009
- The cost of biopharmaceutical R&D: is biotech different?Managerial and Decision Economics, 2007
- A Breakthrough in R&D for Neglected Diseases: New Ways to Get the Drugs We NeedPLoS Medicine, 2005
- The Courage to Change the Rules: A Proposal for an Essential Health R&D TreatyPLoS Medicine, 2005
- A New Trade Framework for Global Healthcare R&DPLoS Biology, 2004
- Information Feudalism: Who Owns the Knowledge Economy?Contemporary Sociology: A Journal of Reviews, 2003